Clinical Trial Update: Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India [Phase 3]

View source ↗

Summary

Phase 3 trial update of a modified BPaL regimen for pre-extensively drug-resistant and treatment-intolerant multidrug-resistant pulmonary tuberculosis in India.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-responsive Multidrug-resistant Pulmonary Tuberculosis
• Pre-extensively Drug-resistant Pulmonary Tuberculosis
• Treatment-intolerant Multidrug-resistant Pulmonary Tuberculosis

Drugs mentioned

• BPaL (bedaquiline, pretomanid, linezolid)

Snippet

Sponsor: Tuberculosis Research Centre, India | Conditions: Pre-Extensively Drug-Resistant Pulmonary TB, Treatment Intolerant Multidrug-Resistant Pulmonary TB | Phase 3 | Status: UNKNOWN